Guo G, Ye L, Pan K, Chen Y, Xing D, Yan K, et al. New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention. Front Cell Dev Biol. 2020;8(May):1–22.

CAS  Google Scholar 

WHO Coronavirus (COVID-19.) Dashboard. [Cited 2023 January 05]. https://covid19.who.int. 2024;2024.

Zheng J. SARS-coV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678–85.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Ezzikouri S, Nourlil J, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Coronavirus disease 2019—historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum Vaccin Immunother. 2020;16(12):2992–3000.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Curr Opin Virol. 2011;1(6):624–34.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med. 2020;12(546):1–6.

Article  Google Scholar 

Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11(December):1–19.

Google Scholar 

Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021;174(6):811–21.

Article  PubMed  Google Scholar 

Martineau AR, Forouhi NG. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. Ann Oncol. 2020;(January):19–21.

Ntoumi F, Batchi-Bouyou A, Djontu J, Vouvoungui J, Mfoutou C, Ingoba L et al. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individuals. ResearchSquare. 2022:1–11.

Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021;36(6):1–17.

Article  Google Scholar 

CDC COVID-19 after Vaccination. Possible Breakthrough Infection. [Cited 2022 December 30]. https://www.cdc.gov/coronavirus/2019-ncov 2023;2023.

Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691–3.

Article  CAS  PubMed  Google Scholar 

Yan LN, Liu PP, Li XG, Zhou SJ, Li H, Wang ZY, et al. Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front Microbiol. 2022;12(March):1–13.

Google Scholar 

Gudina EK, Ali S, Girma E, Gize A, Tegene B, Hundie GB, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. Lancet Glob Health. 2021;9(11):e1517–27.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):1–6.

Article  Google Scholar 

Psichogiou M, Karabinis A, Poulakou G, Antoniadou A, Kotanidou A, Degiannis D, et al. Comparative immunogenicity of BNT162b2 mRNA vaccine with natural SARS-CoV-2 infection. Vaccines (Basel). 2021;9(9):1–13.

Google Scholar 

Karachaliou M, Moncunill G, Espinosa A, Castaño-Vinyals G, Rubio R, Vidal M, et al. SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Med. 2022;20(1):1–16.

Article  Google Scholar 

Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.

Article  CAS  PubMed  Google Scholar 

Gelanew T, Mulu A, Abebe M, Bates TA, Wassie L, Teferi M, et al. A single dose of ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of two-dose-vaccinated, SARS-CoV-2-infection-Naïve individuals: a longitudinal study in Ethiopian health workers. Vaccines (Basel). 2022;10(6):859.

Article  CAS  PubMed Central  PubMed  Google Scholar 

EPHI. Public Health Emergency Operation Center (PHEOC), Ethiopia COVID-19 pandemic preparedness and response in Ethiopia. Vol. 37, EPHI Weekly bulletin. 2022. Available from: https://www.ephi.gov.et/images/novel_coronavirus/EPHI_-PHEOC_COVID-19_Weekly-bulletin_1_English_05042020.pdf

Ethiopia-COVID-19 vaccine tracker. 5 vaccines approved for use in Ethiopia. https://covid19.trackvaccines.org/country/ethiopia/ (accessed: June 2023).

Awartani F, Qutob NM, Asia MR. Seroprevalence of SARS-CoV-2 antibodies among vaccinated and non-vaccinated adults in the West Bank: results of a repeated cross-sectional study. Vaccines (Basel). 2022;10(8):1–11.

Google Scholar 

Roche. Elecsys Anti-SARS-CoV-2 S Elecsys Anti-SARS-CoV-2 S. 2022;03:1–8.

Roche. Elecsys Anti-SARS-CoV-2 Elecsys Anti-SARS-CoV-2. 2022;4.0:1–6.

Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M, et al. Seroprevalence of antibodies to SARS-CoV-2 in rural households in Eastern Uganda, 2020–2022. JAMA Netw Open. 2023;6(2):E2255978.

Article  PubMed Central  PubMed  Google Scholar 

Li X, Liang C, Xiao X. SARS-CoV-2 neutralizing antibody levels post COVID-19 vaccination based on ELISA method—A small real-world sample exploration. Vaccines (Basel). 2021;9(10):1–10.

CAS  Google Scholar 

Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: a population-based cross-sectional study. PLoS Med. 2021;18(12):1–17.

Article  Google Scholar 

Lin S, Kantor R, Clark E. Coronavirus disease 2019. Clin Geriatr Med. 2021;37(4):509–22.

Article  PubMed Central  PubMed  Google Scholar 

Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57–65.

Article  CAS  PubMed  Google Scholar 

Hussein AARM, Hashem MK, Azizeldine MG, Shaddad AM. Prevalence and characteristics of COVID 19 vaccine breakthrough infection in Upper Egypt. Egypt J Bronchol. 2023:0–7.

Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021;13(10).

Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, Natarajan K, Yang DH, Rao S, Klein NP, Irving SA. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19–like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity—nine states, January–September 2021. MMWR. 2021;70(44):1539.

CAS  PubMed Central  PubMed  Google Scholar 

Meyers J, Windau A, Schmotzer C, Saade E, Noguez J, Stempak L, et al. SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays. Diagn Microbiol Infect Dis. 2022;104(4):115803.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Sasikala M, Shashidhar J, Deepika G, Ravikanth V, Krishna VV, Sadhana Y, et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect. 2021;108(February):183–6.

Article  CAS  Google Scholar 

Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2022;3(1):e21–31.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health - Europe. 2021;11:1–7.

Google Scholar 

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121–30.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Madariaga MLL, Guthmiller JJ, Schrantz S, Jansen MO, Christensen C, Kumar M, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2021;289(4):559–73.

Article  CAS  PubMed  Google Scholar 

Otsubo N, Fukuda T, Beppu H, Maki C, Yasui F, Hanawa T, et al. Reduced antibody response to SARS-CoV-2 in COVID-19 patients with newly diagnosed diabetes: a retrospective observational study. BMC Endocr Disord. 2023;23(1):1–11.

Article